of Lyumjev in Patients With COVID-19
is an infectious respiratory disease caused by new variations of
the virus SARS-CoV-2, previously referred to as "2019
has not studied the use of Lyumjev in patients with COVID-19 nor in
patients at risk of contracting COVID-19.
should use their clinical judgment in determining the most
appropriate approach in treating a patient with Lyumjev who has been
exposed to or has confirmed or suspected COVID-19.
Disease Resources for COVID-19
current information on COVID-19, please refer to
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed March 18, 2020.
Tang X, Wu C, Li X, et al. On the origin and continuing evolution of
SARS-CoV-2. Natl Sci Rev. Published online March 3, 2020.
Coronavirus disease (COVID-19) outbreak. World Health Organization
Europe. Accessed March 20, 2020.
International Diabetes Federation Europe. COVID-19 outbreak:
guidance for people with diabetes.
Accessed March 18, 2020
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
= coronavirus disease 2019
= Eli Lilly and Company
= severe acute respiratory syndrome coronavirus 2
= ultra rapid lispro
WHO = World Health Organization (European regional office)
= International Diabetes Federation
= European Centre for Disease Prevention and Control
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.